[{"orgOrder":0,"company":"Cook MyoSite","sponsor":"Lipella Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Urology","country":"","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"Tacrolimus","moa":"","graph1":"Urology","graph2":"Phase II","graph3":"Cook MyoSite","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Cook MyoSite \/ Lipella Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Cook MyoSite \/ Lipella Pharmaceuticals"}]

Find Clinical Drug Pipeline Developments & Deals by Cook MyoSite

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : The collaboration aims to facilitate Chemistry, Manufacturing, and Control documentation for Lipella's drug candidate LP-10 (liposomal tacrolimus), aimed at treating hemorrhagic cystitis. LP-10 has been granted Orphan Drug Designation by the FDA.

                          Brand Name : LP-10

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          April 17, 2023

                          Lead Product(s) : Tacrolimus

                          Therapeutic Area : Urology

                          Highest Development Status : Phase II

                          Sponsor : Lipella Pharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank